Search results for "Blood glucose"

showing 10 items of 437 documents

Risk of progression to diabetes and mortality in older people with prediabetes: The English longitudinal study on ageing

2022

Abstract Aims Prediabetes is used to identify people at increased risk for diabetes. However, the importance of prediabetes in older populations is still poorly explored. Therefore, we aimed to investigate the prevalence of prediabetes, based on either glycated haemoglobin (HbA1c) levels or fasting glucose (FG) levels, or both and the progression of prediabetes to diabetes or to mortality in older participants of the English Longitudinal Study on Ageing. Materials and methods Prediabetes was categorized based on HbA1c levels (5.7%–6.4%) and/or FG levels (5.6–7.0 mmol/L). Information regarding mortality and incident diabetes were recorded during follow-up period of 10 years. Results In 2027 …

Glycated HemoglobinBlood GlucoseMaleAgingGlycated Hemoglobin AdiabetesEnglish Longitudinal Study on Ageing (ELSA)prediabetesGeneral MedicineEnglish Longitudinal Study on Ageing (ELSA); diabetes; older people; prediabetes; Aged; Aging; Blood Glucose; Female; Glycated Hemoglobin A; Humans; Longitudinal Studies; Male; Risk Factors; Prediabetic Stateprediabetes diabetes older people English Longitudinal Study on Ageing (ELSA)older peoplePrediabetic StateRisk FactorsHumansFemaleLongitudinal StudiesGeriatrics and GerontologyResearch PaperAgedAge and Ageing
researchProduct

The diabetic cataract: an unusual presentation in a young subject: case report.

1997

This case report concerns a 14-year-old female patient, whose insulin-dependent diabetes mellitus was displayed by one infrequent complication, the cataract. This is an unusual manifestation in a 14-year-old patient; indeed, there are many findings in experimental animals demonstrating the development of this complication by maintaining blood glucose levels above 12 mM. After surgical therapy, complete vision was recovered, but we think that an earlier diagnosis and therapy of metabolic derangement of diabetes may have avoided this complication.

GlycosuriaBlood Glucosemedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismEye diseaseHypercholesterolemiaCataract ExtractionKetone BodiesCataractEndocrinologyGlycosuriaDiabetes mellitusFemale patientInternal MedicinemedicineHumansHypertriglyceridemiaMetabolic derangementbusiness.industrymedicine.diseaseDiabetic cataractSurgeryDiabetes Mellitus Type 1FemalePresentation (obstetrics)medicine.symptomComplicationbusinessJournal of diabetes and its complications
researchProduct

Pancreatic Extracts for the Treatment of Diabetes (1889-1914): Acomatol.

2019

Background Historical review on the early development of organotherapy for diabetes [pancreatic extracts (PE)] and its relationship with the social and political circumstances. Areas of uncertainty The diagnosis of diabetes relied only in the presence of glycosuria and cardinal symptoms. Blood glucose determinations were not regularly available, requiring large volumes for sampling. Micromethods for glycemia were developed just in the last years of the investigated period. Hypoglycemia remains undiscovered. Isolation and purification of PE were difficult tasks due to the unknown chemical structure of the antidiabetic hormone. Data sources (1) Berliner Medizinhistoriches Museum der Charite (…

GlycosuriaBlood Glucosemedicine.medical_specialtyPancreatic diseasemedicine.medical_treatmentMEDLINEPancreatic Extracts030204 cardiovascular system & hematologyHypoglycemia03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusmedicineDiabetes MellitusHumansHypoglycemic AgentsPharmacology (medical)030212 general & internal medicinePancreasPharmacologybusiness.industryHistory 19th CenturyGeneral MedicineHistory 20th CenturyOrganotherapymedicine.diseaseEndocrine pharmacologyFamily medicinePancreatectomymedicine.symptombusinessAmerican journal of therapeutics
researchProduct

Ajūrvēda individualizētā cukura diabēta terapijā

2015

Definējot iekļaušanas un izslēgšanas kritērijus, tika veikts randomizēts divu grupu, placebo un kontroles grupas, prospektīvs pētījums, kurā tika iekļauti 32 pacienti. Pirmās pētījuma grupas pacienti lietoja Ajūrvēdas medikamentus kombinācijā ar konvencionālu ārstēšanu un otrās grupas pacienti lietoja placebo medikamentus kombinācijā ar konvencionālu ārstēšanu. Nepieciešami precīzāki iekļaušanas kritēriji, lai veiktu stratificētu nejaušās izlases pētījumu gan Prakriti, gan Vikriti apakšgrupās. Tas nodrošinātu adekvātu pacientu skaitu abās apakšgrupās, pirms statistiskās analīzes veikšanas. Tika pamatota korelācija starp ĶMI/aptaukošanos un 2.tipa cukura diabētu. Trīs mēnešu laikā glikoze tu…

Hba1cDiabetes MellitusAyurvedaFasting Blood GlucoseMedicīnaBody Mass Index
researchProduct

Plasma Insulin Levels and Hypoglycemia Affect Subcutaneous Interstitial Glucose Concentration

2018

[EN] Background: Continuous glucose monitoring (CGM) accuracy during hypoglycemia is suboptimal. This might be partly explained by insulin or hypoglycemia-induced changes in the plasma interstitial subcutaneous (SC) fluid glucose gradient. The aim of the present study was to assess the role of plasma insulin (PI) and hypoglycemia itself in the plasma and interstitial SC fluid glucose concentration in patients with type 1 diabetes mellitus. Methods: Eleven subjects with type 1 diabetes (age 36.59.1 years, HbA(1c) 7.90.4% [62.8 +/- 2.02mmol/mol]; mean +/- standard deviation) were evaluated under hyperinsulinemic euglycemia and hypoglycemia. Each subject underwent two randomized crossover clam…

Hypoglycemia; Interstitial glucose; Subcutaneous glucose sensing; Endocrinology Diabetes and Metabolism; Endocrinology; Medical Laboratory TechnologyAdultBlood GlucoseMalemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismHypoglycemiaAffect (psychology)03 medical and health sciences0302 clinical medicineEndocrinologySubcutaneous glucose sensingInternal medicineDiabetes mellitusMedicineHumansInsulinskin and connective tissue diseases030304 developmental biology0303 health sciencesbusiness.industryContinuous glucose monitoringInsulinnutritional and metabolic diseasesInterstitial glucoseExtracellular FluidMiddle Agedmedicine.diseaseHypoglycemiaINGENIERIA DE SISTEMAS Y AUTOMATICA3. Good healthDiabetes and MetabolismMedical Laboratory TechnologyEndocrinologyDiabetes Mellitus Type 1GlucoseInterstitial glucoseFemalesense organsPlasma insulinbusiness
researchProduct

Pre-Exercise Blood Glucose Levels Determine the Amount of Orally Administered Carbohydrates during Physical Exercise in Individuals with Type 1 Diabe…

2019

The aim of the study was to assess the amount of orally administered carbohydrates needed to maintain euglycemia during moderate-intensity exercise in individuals with type 1 diabetes. Nine participants with type 1 diabetes (four women, age 32.1 &plusmn

Insulin degludecAdultBlood GlucoseMalemedicine.medical_specialtyinsulintype 1 diabetesmedicine.medical_treatmentcarbohydratesBlood sugar030209 endocrinology & metabolismPhysical exerciselcsh:TX341-641Article03 medical and health sciencesYoung Adult0302 clinical medicineOxygen ConsumptionInternal medicineDiabetes mellitusmedicineDietary CarbohydratesHumansType 1 diabetesNutrition and DieteticsCross-Over Studiesexercisebusiness.industryInsulin030229 sport sciencesmedicine.diseaseCrossover studyHypoglycemiaBicyclingEndocrinologyDiabetes Mellitus Type 1Blood chemistryFemaleeuglycemiabusinesslcsh:Nutrition. Foods and food supplyFood ScienceNutrients
researchProduct

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

Insulin degludecBlood GlucoseMalemedicine.medical_treatmentDEVOTE Study GroupInsulin GlargineType 2 diabetesKaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventiondiabetes ; insulin0302 clinical medicineRandomized controlled triallawCardiovascular DiseaseGLUCOSE CONTROL11 Medical and Health SciencesRISKCOMPLICATIONSOUTCOMESIncidenceGeneral MedicineMiddle AgedInsulin Long-ActingVARIABILITYCardiovascular Diseasesdiabetes mellitusFemaleLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialty030209 endocrinology & metabolismAged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin Long-Acting; Kaplan-Meier Estimate; Male; Middle Aged; Medicine (all)HypoglycemiaBedtimeArticleEVENTS03 medical and health sciencesHYPOGLYCEMIAMedicine General & InternalDouble-Blind MethodInternal medicineDiabetes mellitusGeneral & Internal MedicinemedicineHumansHypoglycemic AgentsIntensive care medicineMETAANALYSISAgedScience & TechnologyHypoglycemic AgentInsulin glarginebusiness.industryInsulinmedicine.diseaseDiabetes Mellitus Type 2businessBASAL INSULIN
researchProduct

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?

2019

The interesting article by Yamabe et al.1 showed, using continuous glucose monitoring, that insulin degludec (I‐Deg) was associated with a high percentage of time with nocturnal hypoglycemia than with insulin glargine 300 U/mL (I‐G300; P = 0.02). However, we observe that some possible confounding factors might have influenced the results, such as differences in concomitant medications, use of the same titration protocol for both kinds of insulin or differences in glucose levels. This is also a recurrent problem in clinical trials, which sometime produce conflicting results. In fact, the study of Yamabe et al. is partly in agreement with some recently published clinical trials that gave diff…

Insulin degludecBlood Glucosemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentdiabetes insulin clinical trials hypoglicemiaInsulinsInsulin GlargineHypoglycemiaDiseases of the endocrine glands. Clinical endocrinologyInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsLetters to the EditorLetter to the EditorGlycated HemoglobinInsulin glarginebusiness.industryInsulinBlood Glucose Self-Monitoringnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseRC648-665HypoglycemiaClinical trialInsulin Long-ActingEndocrinologyDiabetes Mellitus Type 2businessmedicine.drug
researchProduct

Continuous glucose monitoring use and glucose variability in very young children with type 1 diabetes (VibRate): A multinational prospective observat…

2021

While data on the efficacy and safety of continuous glucose monitoring (CGM) exist across a broad age spectrum, it is limited in very young children with type 1 diabetes (T1D). We aimed to assess real-world data in this high-risk population, focusing on glycemic variability and metrics beyond HbA1c. A 12-month multi-national, prospective, observational, registry-based cohort study in children with T1D aged 1-7 years compared glucose control using real-time CGM and using fingerstick blood glucose monitoring (BGM) alone. The prespecified primary endpoint was a difference in coefficient of variation (CV) between the CGM users and BGM-only cohort. Among 227 individuals using insulin pumps (42% …

Insulin pumpBlood GlucosePediatricsmedicine.medical_specialtyendocrine system diseasesFingerstickEndocrinology Diabetes and MetabolismPopulationChildren; Continuous glucose monitoring; Insulin pump; Toddlers; Type 1 diabetesCohort StudiesHDE END PEDEndocrinologyInsulin Infusion SystemsInternal MedicinemedicineHumansHypoglycemic AgentsInsulinInsulin pumpeducationChildChildrenContinuous glucose monitoringchildren; continuous glucose monitoring; insulin pump; toddlers; type 1 diabetesGlycemicBlood glucose monitoringGlycated HemoglobinToddlerseducation.field_of_studyType 1 diabetesmedicine.diagnostic_testEndocrinology; Metabolismbusiness.industryBlood Glucose Self-Monitoringnutritional and metabolic diseasesDiabetes type 1medicine.diseaseType 1 diabetesDiabetes Mellitus Type 1GlucoseChild PreschoolCohortbusinessCohort studyDiabetes Obesity & Metabolism
researchProduct

Glycemic Outcome Associated With Insulin Pump and Glucose Sensor Use in Children and Adolescents With Type 1 Diabetes. Data From the International Pe…

2021

OBJECTIVE Insulin delivery methods, glucose-monitoring modalities, and related outcomes were examined in a large, international, diverse cohort of children and adolescents with type 1 diabetes from the Better Control in Pediatric and Adolescent Diabetes: Working to Create Centers of Reference (SWEET) -Registry. RESEARCH DESIGN AND METHODS Participants with type 1 diabetes of >= 1 year, aged <= 18 years, and who had documented pump or sensor usage during the period August 2017-July 2019 were stratified into four categories: injections-no sensor (referent); injections + sensor; pump-no sensor; and pump + sensor. HbA(1c) and proportion of patients with diabetic ketoacidosis (DKA) or severe hyp…

Insulin pumpKetoacidosisBlood Glucosemedicine.medical_specialtyDiabetic ketoacidosisAdolescentEndocrinology Diabetes and MetabolismDpv030209 endocrinology & metabolismHypoglycemia03 medical and health sciences0302 clinical medicineInsulin Infusion SystemsDiabetes mellitusInternal medicineInternal MedicinemedicineHumansHypoglycemic AgentsInsulin030212 general & internal medicineRegistriesChildGlycemicAdvanced and Specialized NursingGlycated HemoglobinType 1 diabetesbusiness.industryBlood Glucose Self-Monitoringmedicine.diseaseQualityHypoglycemiaKetoacidosisDiabetes Mellitus Type 1CohortTherapybusinessDiabetes Care
researchProduct